Iasonfluoride (Sodium Fluoride (18f))

Sodium Fluoride, the active ingredient in Iasonfluoride, is a fluoride presented as a solution for injection for intravenous use. It is employed to correct systemic fluoride deficiency and to help prevent dental caries in individuals at risk.

GNH USA supplies Iasonfluoride as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement agencies worldwide, adhering to EU quality standards and providing reliable cold‑chain logistics for injectable products. The company ensures batch traceability, regulatory compliance and on‑time delivery to support patient care across diverse health systems.

Iasonfluoride, a systemic fluoride preparation, is used in clinical situations that involve fluoride deficiency or high risk of tooth decay. - Fluoride deficiency: restores normal systemic fluoride levels to support bone and tooth mineralization. - Prevention of dental caries: reduces incidence of enamel demineralization and promotes remineralization in patients prone to cavities. - High‑risk dental patients: provides supplemental fluoride to individuals undergoing orthodontic treatment or with reduced salivary flow.

Iasonfluoride may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Vomiting: occasional episodes following infusion. - Abdominal pain: transient discomfort in the stomach area. - Headache: mild headache during or after administration. - Injection site pain: local tenderness or erythema at the infusion site. - Mild hyperfluorosis: temporary skin discoloration or mottling.

Serious or Rare Side Effects: - Severe hyperfluorosis: systemic toxicity with bone pain and joint stiffness. - Cardiac arrhythmia: irregular heart rhythm potentially requiring monitoring. - Hypotension: significant drop in blood pressure during infusion. - Anaphylaxis: acute allergic reaction with respiratory distress. - Renal toxicity: impaired kidney function in susceptible patients. - Severe allergic reaction: urticaria, angioedema, or bronchospasm.

Prior to using Iasonfluoride, clinicians should consider several safety measures to minimise risk. - Renal function: assess baseline kidney function and adjust use in renal impairment. - Pregnancy: avoid unless benefit outweighs potential risk, as safety data are limited. - Pediatric use: dose must be individualized; monitor growth and fluoride exposure. - Calcium supplements: avoid concurrent high‑dose calcium which may reduce fluoride efficacy. - Extravasation: monitor infusion site and stop if leakage occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iasonfluoride can interact with other medicines, altering its effectiveness or safety profile.

Major Interactions (Avoid): - Calcium‑containing antacids: form insoluble complexes that reduce fluoride absorption. - Tetracycline antibiotics: chelate fluoride ions, decreasing antimicrobial activity. - High‑dose vitamin D: may increase systemic fluoride retention and risk of toxicity.

Moderate Interactions (Monitor Closely): - NSAIDs: concurrent use may affect renal clearance of fluoride. - Loop diuretics: can modify electrolyte balance and influence fluoride excretion. - ACE inhibitors: may potentiate hypotensive effects during infusion.